Home Watchlists Portfolios Indices Forex Futures Market Scan Chart Settings

AstraZeneca's (AZN) Buy Rating Reaffirmed at Shore Capital



  • Source: Slater Sentinel - - Read: 0

    Summary:

     

    AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities researchers at Shore Capital in a report released on Friday, August 9th, Digital Look reports.

    Other equities research analysts also recently issued research reports about the stock. UBS Group restated a “sell” rating and issued a GBX 5,400 ($70.56) target price on shares of AstraZeneca in a research note on Thursday, July 25th. Goldman Sachs Group boosted their target price on shares of AstraZeneca from GBX 5,000 ($65.33) to GBX 5,500 ($71.87) and gave the company a “sell” rating in a research note on Monday, August 5th. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a research note on Wednesday, August 7th. Credit Suisse Group set a GBX 7,300 ($95.39) target price on shares of AstraZeneca and ...

     

     

    Read Full News: https://slatersentinel.com/news/2019/08/16/astrazeneca-lonazn-stock-rating-reaffirmed-by-shore-capital.html


Log in to reply